HIV and ID Observations

An ongoing dialogue on HIV/AIDS, infectious diseases,
all matters medical, and some not so medical.

Recent Posts

October 14th, 2019

Common Questions About the Shingles Vaccine — Answered Here!

National Library of Medicine

Here’s an interesting email from my friend and ID-colleague Dr. Carlos Del Rio (shared with his permission):

Went Tuesday to see my PCP for a routine visit and had my second dose of Shingrix that day. I had gotten my first dose about 3 months ago and had severe chills and even a fever of 38.5 after the first dose. With the second dose the response was not as severe but did have chills and rigors for about 18 hrs. Stupid of me, but the next day I went to get my labs checked, and everything was fine except my HS-CRP which was 14.72 (nl < 10 and in the past I had been < 1.0).

Anyway…..Shingrix is a good vaccine but it is a tough one to take and really gives you a nice TNF storm!

For the few of you out there in ID-World who don’t know him, you must understand it takes quite the force to slow down the high-energy machine that is Carlos. He is the very definition of indefatigable. So it’s not surprising he told me he went to work after both shots, rigors and all.

(Brief aside — congratulations, Carlos, on your well-deserved award!)

But Carlos’ post-shingles vaccine experience reminds me that we’re now two years into the recombinant zoster vaccine (RZV, Shingrix) era, and that immunization for this common adult infection — shingles, or zoster — has brought with it all sorts of new questions.

So here are a bunch of common ones we ID doctors field on a regular basis:

  • Who should get it? The vaccine is recommended for essentially all immunocompetent people over 50. So if you were born anytime before October 1969, this means you. People conceived during the Woodstock music festival or right after the Miracle Mets won the World Series are off the hook, at least for a few months longer. Two shots, separated by 2-6 months.
  • “Immunocompetent” adults — so nobody else? While immunosuppression is not a contraindication to the RZV, the data supporting its use in this population have not yet informed current guidelines. For now, it’s totally reasonable to offer RZV to people over 50 receiving low-dose immunosuppression, or to those with stable HIV on treatment, or to individuals who have had an autologous stem cell transplant. For higher degrees of immunosuppression, adopt an individualized approach — and remember that there is a theoretical concern that the adjuvant in the vaccine might stimulate organ rejection or a flare of an underlying autoimmune condition. We’ll see if this turns out to be a legitimate worry, so far it hasn’t.
  • No upper age limit? Use your judgment — if it’s a healthy 88-year-old with few medical problems, go ahead and give it. The risk of shingles increases as we age, and such a person will likely live several more years and could benefit from the vaccine. However, if it’s someone with multiple serious comorbid medical problems, then skip it. And yes, there are side effects — see Carlos’ email — which might be difficult for the frail elderly to tolerate.
  • What about people younger than 50 who have had shingles? While it’s understandable that they might be interested in the vaccine, it’s not been tested in people under 50, and is not formally recommended in this group. Reassure them that recurrent shingles is actually quite rare, especially within the first few years of an attack.
  • My patient never had chickenpox. Should they still get the zoster vaccine? Generally yes. For people born in the U.S. before 1980, essentially all have latent infection with varicella zoster virus — they either had a mild case of chickenpox or don’t remember having it. There might be a small fraction of people over 50 who never had chickenpox, test negative for antibody, and don’t want to risk the side effects of the vaccine. For them, consider the vaccine optional! (Many would recommend the chicken pox vaccine instead.)
  • How long after a case of shingles should my over-50 patient wait before getting the vaccine? No one knows. But since active zoster boosts a person’s immune response, it makes sense to wait at least until the current episode has completely resolved. I then add some additional time derived from the sophisticated ID time machine calculators. “At least 6 months” sounds reasonable, doesn’t it?
  • We had a shortage of the vaccine, now it’s now been more than 6 months since some of our patients had their first dose. Do they need to start over? Fortunately (for many reasons), no. Just give it when it becomes available.
  • Speaking of the shortage, what’s going on? Because of high demand for the vaccine, there have been widespread shortages of RZV ever since the vaccine became available. While these seem to have eased somewhat, especially in the last 6 months, not all practices or clinics or hospitals have it in stock. Fortunately, there’s a handy vaccine finder tool that I hear is quite reliable for pharmacies that offer the vaccine. Many hospital-based clinics also have it (we do).
  • Should I still give the new vaccine to people who got the old one? Definitely — not only is the RZV vaccine more effective, but that original live-virus vaccine (Zostavax) becomes less effective over time, and works less well when given to older patients, especially those over 70. If your patient got the live virus vaccine more than 6 years ago, they may not have any residual protection at all.
  • I hear the side effects are pretty bad — could they be worse than shingles? While no doubt the new zoster vaccine causes more side effects than most other vaccines, the clinical trials showed that serious side effects — those leading to death, hospitalization, need for urgent medical care — were no more common in vaccine recipients than in those who got placebo. Educate your patients that they might experience arm pain, fevers, fatigue, and myalgias and that these symptoms could be bad enough to have an impact on their daily activities. (This happened in 17% of study participants.) What this means practically is that I don’t recommend giving the zoster vaccine the day before a major life event, travel, or a demanding job requirement. And no harm taking a dose of acetaminophen or ibuprofen for symptom control.

But let’s go back to Carlos for a moment, and how these side effects he experienced compare to herpes zoster:

And to be clear, Shingrix side effects way milder than having shingles!

Completely agree! My experience — arm pain (check), fatigue (check), myalgias (check), and low-grade fever (check). But it was all over in a day, I promise.

And with the acknowledgment that we ID doctors see cases of zoster on the more severe end of the disease spectrum, we have all seen shingles accompanied by a host of really nasty complications. These include encephalitis, stroke, facial nerve paralysis, corneal involvement, vertigo, bacterial superinfection, and, most commonly, disabling unremitting pain (post-herpetic neuralgia) — pain for which there is often little effective therapy.

So the simple answer to the last question — are the side effects from the vaccine worse than shingles? — my answer is an emphatic no! I still strongly recommend it for my patients, colleagues, and friends of a certain age.

And look, my colleagues agree:

Back to the Summer of ’69 (the real one) …

(H/T, as always, to the incomparable Immunization Action Coalition site for clear, helpful information.)

Categories: Health Care, Infectious Diseases, Patient Care
Tags: , , ,

(31) Comments
Permalink

October 7th, 2019

Our HIV Testing Algorithm Has a Major Problem — Here’s How to Fix It

Mostly, HIV testing works great. It’s long been so accurate that we can strongly support HIV testing even in relatively low-risk people.

The 2014 revised lab testing guidelines made it even better, recommending a combined antigen/antibody screening test (called the 4th generation test), and replacing the Western blot with the HIV-1/2 differentiation immunoassay as the preferred confirmatory test.

However, if you’re a primary care, ID/HIV, or OB/GYN clinician who sends a lot of HIV tests, you’ve no doubt received the following perplexing result::

4th Generation Human Immunodeficiency Virus (HIV) Combination Antigen/Antibody:  Repeatedly Reactive

HIV-1/2 Antibody Differentiation Immunoassay:  Negative

Interpretation:  INDETERMINATE for HIV-1/2.

There are many problems with this outcome, which is common enough that it turns out to be the most common question about HIV testing by far. But three years have passed since I last addressed it, so let’s explore again and figure out how to fix it.

First, the reasons it’s so problematic:

  1. In patients at high risk for HIV, this is a critical result that should prompt rapid action. An indeterminate result with a positive HIV screen and negative HIV-1/2 differentiation assay could be acute HIV — patients may be in the “window” period before they have developed a sufficient antibody response. Why? It’s worth remembering that when we moved from the 3rd- to the 4th-generation screening test, we shortened the window period by adding p24 antigen to the screening test only. It’s now around 14 days after HIV acquisition. By contrast, the confirmatory differentiation test still only detects antibody. Window period for this test? A median of 33 days. And that difference may occur exactly when people with acute HIV are most symptomatic. Bad.
  2. In patients at low risk for HIV, this is a confusing result that almost never means anything and prompts only worry. Since we appropriately do a lot of HIV testing in low-risk people — especially pregnant women — the prior probability that they actually have acute HIV is extraordinarily low, especially if they are asymptomatic. The screening test’s 99.6% specificity is great (Lyme testing is jealous). But this means that around 4/1000 times, the HIV test will be positive even in a person without HIV — the prevalence of acute HIV in most screened populations is way lower than that. As a result, in many centers (including ours), most of the reactive HIV screens with negative confirmatory tests ultimately end up being false-positive screens.
  3. Sorting out what your patient has — acute HIV or a false-positive HIV screen — is straightforward medically, but far from easy from a logistical perspective. Sure, a subsequent negative quantitative HIV viral load means it’s a false positive, and a positive one (at pretty much any value) indicates acute HIV — simple to interpret medically. But try explaining that to a worried patient on the other end of your notification phone call, or telling them they have to come back in for another test to just be sure that your impression (whatever it may be) is correct. With so much testing done today as a matter of routine screening, we might end up having to do some of the risk assessment over the telephone, a distinctly uncomfortable scenario — especially tricky in an era when lots of our communication is via “patient portals” or some other non face-to-face method. Notably, some labs will “reflex” their indeterminate tests to a qualitative HIV nucleic acid test (NAT), but in discussion with my colleagues around the country, this is far from routine.
  4. Most medical centers can offer turnaround on a quantitative HIV viral load far faster than the HIV differentiation assay. This is particularly true if the screening test is done at your hospital’s lab, with reactive tests then sent to a reference laboratory. In our hospital, for example, when clinicians suspect acute HIV — patient may be at risk, or have symptoms — they often appropriately send an HIV viral load at the time of initial presentation. We then have this bizarre outcome where the HIV screen returns positive, the viral load comes back very high within a couple of days, and then — after a 3 or 4 day further delay — the differentiation assay return negative. In one such case, the HIV resistance genotype was also ordered at baseline, and it came back before the (negative) differentiation test!
  5. The tests are a nonsense word salad smothered with Thousand Island dressing. Read that result at the top in its entirety — what a bunch of gobbledygook. Look, we ID/HIV specialists know what these words mean, but ask some primary care clinicians or obstetricians, they will have no idea. Or ask them what it’s like to enter “HIV” in the order box of their electronic medical record. Chaos! (See image on the right — click on it for the full effect.) It’s completely understandable why they might be confused — this isn’t their specialty. So read the tests again, and pity the non-ID specialists: 4th Generation Human Immunodeficiency Virus (HIV) Combination Antigen/Antibody.  HIV-1/2 Antibody Differentiation Immunoassay. Good grief. How about just, “HIV screening test” and “HIV confirmatory test”?

How can we fix this? As usual when it comes to HIV testing, we turn to the top expert in this area, Dr. Bernie Branson. Fortunately for all of us, he just wrote a sensational review of HIV testing for Infectious Disease Clinics.

Here’s what Bernie says:

With current technology, it would be more efficient to reverse the current confirmatory testing sequence and, after a reactive Ag/Ab combination assay, perform a quantitative HIV-1 RNA viral load test to both confirm the diagnosis and contribute to immediate clinical management.

Of course! Confirm the reactive screen with an HIV-1 viral load! How sensible! This will give us the most critical result much more rapidly.

A detectable (at almost any level) HIV-1 viral load would prompt immediate HIV therapy, important for reducing HIV transmission, preserving immune function, and possibly providing our best candidates for HIV cure strategies when they become available.

With a negative HIV-1 viral load, the HIV-1/2 antibody assay (done next) would pick up the small proportion of those who are elite controllers, or are on ART and haven’t told you (HIV-1 antibody positive, viral load negative); have HIV-2 (HIV-2 antibody positive); or just had a false-positive HIV screen (HIV-1/2 antibody negative).

And those worried about a (slight) delay in diagnosis for HIV-2? This will occur rarely — with the prevalence of HIV-2 in this country exceedingly low, a CDC scientist recently described the routine use of this test as “High Burden, Low Yield”. 

So what are the barriers to making this change a reality?

  • There is no FDA-approved quantitative viral load test for HIV diagnosis. There is a qualitative HIV viral load test approved, but it is not widely available, requires plasma (see below), and a positive result would still warrant doing the quantitative test. According to Bernie’s paper, some are available internationally. Time to bring them here!
  • Many labs draw serum, not plasma, when doing HIV testing. Available quantitative viral load tests have been validated on plasma only. This makes the “reflex” strategy cited above in item #3 impractical. Apparently, serum-based quantitative viral load tests are also available in other countries.
  • Viral load testing is much more expensive. Tests considered “molecular” by payers cost a ton, even though the technology to do them has dramatically improved and become more efficient. This progress should theoretically make them more affordable, but some labs may be reluctant to give up the high price and revenues.

The above issues are not insurmountable barriers, but they will take time to overcome. But as an optimist by nature, I’m convinced this will happen — it just makes too much sense. And look, you apparently agree:

Until then, we’re stuck with this strange situation where the “confirmatory” test ironically may not confirm anything at all — either during acute HIV, or when the screening test is a false positive.

Fortunately, it doesn’t have to be this way — time to make the change!

Categories: Health Care, HIV, Infectious Diseases, Patient Care, Policy
Tags:

(12) Comments
Permalink

September 28th, 2019

What Is the Best Treatment for Advanced HIV Disease?

One of the things that keeps me on Twitter — besides cute dog videos — is the periodic realization that the platform can help patients.

Which is, after all, why most of us do this doctor thing — to help people get better.

Example:

So let’s consider this case from the energetic and amusing Canadian ID doctor Sebastien Poulin, which he posted a couple of weeks ago.

He was kind enough to share a few more details of the case with me via email (certain details slightly changed):

Middle-aged man admitted with fatigue and weight loss. Evaluation notable for oropharyngeal candidiasis, moderate pancytopenia, intra-abdominal lymphadenopathy (mesenteric and perihepatic), homogeneous hepatomegaly without splenomegaly.

HIV test positive. CD4 13; HIV RNA 2 million. Started on TDF/FTC, dolutegravir. Also TMP/SMX for PCP prophylaxis.

Three weeks later, blood culture turns positive for M avium complex.

Two questions immediately occurred to me with this challenging case:

Question #1:  Is this this TDF/FTC plus DTG regimen the optimal choice, or should we add (or use) boosted darunavir?

Certainly TDF/FTC plus DTG is a guidelines-endorsed first-line regimen, and the clinical trials of DTG as first-line therapy demonstrate good activity across a broad range of baseline viral loads and CD4 cell counts.

But consider the three case reports of treatment failure with emergent DTG resistance in initial treatment with three-drug therapy:

  1. Fulcher, et al, Clin Infect Dis 2018;67(5):791-4:  HIV RNA — 1,970,000. CD4 — 78. Active infection — PCP.  Relevant concomitant medications — None.
  2. Pena MJ, et al. Open Forum Infect Dis 2019;6(1):ofy332:  HIV RNA — 457,000. CD4 — 39. Active infection — Staph aureus.  Relevant concomitant medications — rifampin (DTG dosed twice-daily).
  3. Lübke N, N Engl J Med 2019; 381(9):887-9:  HIV RNA — 1,400,000. CD4 — 22. Active infection — TB.  Relevant concomitant medications — rifabutin (DTG dosed once-daily). [Special note from me: got to love when OFID scoops the NEJM!]

All of these cases involved people with HIV who had advanced HIV disease, high viral loads, and active infections. All ultimately achieved viral suppression with inclusion of darunavir-based therapy.

Remember, patients like this, or the case posted by Sebastien, did not qualify for the registrational clinical trials of dolutegravir. Even stable patients with severe immunosuppression and high viral loads were uncommon. The same limitation applies to studies of bictegravir/FTC/TAF.

In contrast, consider the NAMSAL study — 66% of entrants had a viral load of ≥100,000, and 31% had a viral load of ≥500,000. Responses to both the efavirenz and DTG-based strategies was notably lower in these participants.

So how comfortable should we be using DTG or BIC-based regimens in someone with a baseline viral load of 2 million and a CD4 cell count of 13? An ongoing clinical trial might help us answer the question, but until results are available, what to do?

Question #2:  Should rifabutin be part of the treatment for MAC?

In a prospective, comparative clinical trial of treatment for HIV-related disseminated MAC, the three-drug regimen of clarithromycin, ethambutol, and rifabutin improved survival compared with either clarithromycin plus ethambutol or clarithromycin plus rifabutin.

So the answer to this Question #2 seems pretty obvious. Yes!

But we might wonder whether these data are still relevant to Sebastien’s case. Only 14% of the participants in that study were receiving PI-based ART. Plus, the study enrolled from 1994-1998, when combination ART was markedly less effective and more toxic than today — and was especially difficult to tolerate for patients with advanced HIV disease and active opportunistic infections.

As a result, the current OI guidelines say the following about adding a third drug for disseminated MAC:

Some experts would recommend addition of a third or fourth drug for people with HIV with high mycobacterial loads (i.e., >2 log CFU/mL of blood), or in the absence of effective ART.

You know that whenever the “Some experts” phrase makes an appearance, there are no strong data to direct us one way or another. And who these days knows a patient’s quantitative “mycobacterial load”?

Let’s look again at our cases of dolutegravir failure with resistance — two out of three received rifamycin drugs. Rifampin strongly induces DTG metabolism, which requires doubling the dose to 50 mg twice daily (the clinicians did this in case #2). Rifabutin has much less of an effect, so no change in dose is required. Still, experience with rifabutin and dolutegravir in clinical practice must be quite limited.

So back to our questions:

  1. Is this this TDF/FTC plus DTG regimen enough, or should we add (or use) boosted darunavir?
  2. Should rifabutin be part of the treatment for MAC?

Let’s do a poll on #1. Please use the comments section to let us know why you made your choice, as well as your thoughts on the rifabutin quandary in question 2.

What would you use for intial HIV therapy in this case?

View Results

As for cute dog videos, there’s this:

Categories: Health Care, HIV, Patient Care
Tags: , , ,

(7) Comments
Permalink

September 15th, 2019

A Former Medical School Dean Invents a False Dichotomy in Curriculum Content, and Advises Physicians to Stay in Their Lane

Aristotle, who famously said this.

Over on the editorial pages of the Wall Street Journal, a piece appeared last week with the following provocative title and subtitle:

Take Two Aspirin and Call Me by My Pronouns
At ‘woke’ medical schools, curricula are increasingly focused on social justice rather than treating illness.

Dr. Stanley Goldfarb, former associate dean of curriculum at the University of Pennsylvania, argues that current medical schools focus so much on advocacy, social justice, and various (left-leaning) causes that students don’t have time to learn how to care for patients.

And what are some of the distractions these medical students must endure as they try to master the craft of medicine?

Cultural diversity, gun control, climate change, health disparities. Teaching about these topics “comes at the expense of rigorous training in medical science.”

He cites no actual data that this is true, of course, which means it’s his opinion — an opinion I strongly suspect he harbors based on how he feels about these topics himself.

Regardless of how we feel about them, however, most will recognize the “back in my day we studied real medicine” tone. This one turns up frequently when many of us old-timers weigh in on the state of medical education today, be it in medical school or residency. You know, “back in the days of the Giants”, bringing to mind the “OLD MAN YELLS AT CLOUD” internet meme.

But back to the topic of his piece — is it really a new phenomenon that medical schools include a societal (as well as individual) view of medicine, and that students show interest in these topics?

Absolutely not — back when I went to medical school a million years ago (ok, in the early 1980s), we were urged always to consider our patients in the context of their community, and also to think broadly about what we could do as doctors to improve not just individual, but also community health. While patient care was a the core of our efforts, my classmates ended up choosing a huge range of different passions to pursue.

A quick list: Basic science research. Clinical research. Public health and epidemiology. Health disparities, both here and globally. Domestic healthcare policies. Healthcare finance. Teaching. The medico-legal interface. Investment banking and consulting. One even started her own footwear company!

In short, one of the great things about medical training is that it’s adaptable to a wide range of health-related pursuits. Since what we include in a medical school curriculum cannot possibly cover everything — more true today than ever — why not include topics that are important from a societal level too? Don’t these influence patient outcomes?

Of course they do — sometimes powerfully so, something most University of Pennsylvania doctors readily acknowledge, citing the vast economic disparities evident right there in Philadelphia.

And it appears the University of Pennsylvania agrees, as evidenced by the letter they have sent to students and faculty:

Please know that the views expressed by Dr. Goldfarb in this column reflect his personal opinions and do not reflect the values of the Perelman School of Medicine. We deeply value inclusion and diversity as fundamental to effective health care delivery, creativity, discovery, and life-long learning. We are committed to ensuring a rigorous and comprehensive medical education that includes examination of the many social and cultural issues that influence health, from violence within communities to changes in the environment around us.

Additional Penn faculty quickly weighed in on the editorial, noting that “social and health policies have always determined who gets sick and who gets care, and where, and how.” Unlike in the Wall Street Journal piece, these authors include some clear examples — the Flint Water Crisis, urban gun violence, underdiagnosis of cardiovascular disease in women and depression in African Americans — on how poverty, race, and bias influence individual and public health.

As for Dr. Goldfarb’s opening salvo:

The American College of Physicians says its mission is to promote the “quality and effectiveness of health care,” but it’s stepped out of its lane recently with sweeping statements on gun control.

Don’t get me started.

 

Categories: Health Care, Medical Education, Policy
Tags:

(30) Comments
Permalink

September 8th, 2019

The Curious Case of M184V, Part 2 — and More!

The inspiration for today’s post comes from two recent emails from ID/HIV colleagues — thank you.

Here’s the first, from Dr. Mehri McKellar from Duke:

Hi Paul,

When are you going to do part 2 of The Curious Case of M184V, Part 1?

I am waiting patiently. 🙂

Mehri

Mehri, wait no more, because here it is! And thank you for the reminder, which is quite timely since there’s now greater clarity than ever about M184V, and what to do with that next regimen.

That first post summarized why we even care about this mutation, and what makes it so special — and so curious. Specifically:

  1. It’s the most common NRTI mutation observed with treatment failure. HIV docs averse to memorizing mutations should definitely put this one on their short list anyway — sorry, some you just have to know.
  2. Despite finding it frequently in people on treatment with viremia, we rarely see it transmitted in newly diagnosed patients. Latest data had it at  < 1% in the United States.
  3. M184V is selected by 3TC (lamivudine) or FTC (emtricitabine), leading to high-level phenotypic resistance. Despite this resistance, 3TC and FTC retain some antiviral activity.
  4. It impairs viral fitness. Viruses with M184V just don’t grow as well in vitro.
  5. It improves susceptibility to tenofovir, zidovudine, stavudine. By contrast, it worsens susceptibility to abacavir and didanosine.

Part 1 also mentioned that, despite how common this mutation was in clinical practice, we still didn’t have clarity about the best treatment option with this mutation. The date of that post was May 21st, 2017, and here’s the good news — there’s been quite a bit of progress on this front.

The most important data come from the DAWNING study, which evaluated people who had failed first-line treatment with two NRTIs and an NNRTI, then randomized them to receive either dolutegravir or lopinavir/ritonavir, plus at least one active NRTI as measured by baseline genotype testing.

The study was an overwhelming win for the dolutegravir strategy (84% vs. 70% viral suppression in the DTG vs. LPV/r arms, respectively), prompting early termination of the trial. The results certainly made us much more comfortable using dolutegravir plus NRTIs as a second-line treatment option, even in patients harboring some NRTI resistance.

Not surprisingly, most participants (84% in DTG arm, 81% in LPV/r arm) had M184V at baseline, which if present did not alter the primary study results favoring DTG. Most of the subsequent NRTI regimens chosen included either TDF or ZDV.

(Time for a complex, kind of geeky, digression. DAWNING let the investigators choose what NRTIs they used to combine with DTG or LPV/r. In the WHO guidelines, which assumed no genotypes available, and hence possible K65R, people previously receiving TDF were advised to go on ZDV, and the converse. As a result, it is likely that in DAWNING some of the participants who had M184V alone went on ZDV, even though they didn’t “need” to — tenofovir would have been active. And we hate to use ZDV these days, don’t we? Plus, two people in the study did have subsequent treatment failure with integrase resistance — but none of them had M184V alone.)

So, DAWNING takes care of people who are failing therapy with isolated M184V — the best approach is to give them DTG with at least one active NRTI, with tenofovir the ideal choice, given its enhanced activity (see Point #5, above). Often we’ll keep the FTC (or 3TC) along for the ride, since it’s so nontoxic and, as noted in Point #3, still has some activity.

But what about suppressed patients? What if they have M184V, and you’re interested in switching?

Here we can get some information from the 4030 study, presented this year at IAS. (I was the presenting investigator.) People with viral suppression on DTG plus TAF or TDF/FTC were randomized to TAF/FTC + DTG or to switch to the single pill BIC/FTC/TAF. Unlike most switch studies, prior failure with resistance was permitted, and participants were stratified by NRTI resistance into three groups:

  1. Tenofovir resistance (either K65R or 3 or more TAMS)
  2. Any other NRTI pattern (which includes M184V, either alone or with others)
  3. No NRTI resistance

The overall results demonstrated noninferiority of BIC/FTC/TAF to DTG plus TAF/FTC. These results held up regardless of the baseline resistance category.

Ah, but what about those challenging patients with both tenofovir resistance plus M184v? (This is the and More! part of the title.)

Time for another email, this time from another ID/HIV specialist — Dr. Risa Hoffman, from UCLA!

Hi Paul,

In the study you presented at IAS – did any people have both K65R and M184 (or in other words, resistance to both TAF and FTC/3TC?). We are doing a journal club on the ever-favorite topic of using bictegravir/FTC/TAF or a similar regimen in the presence of NRTI resistance…. I’m still looking for the answer about using this regimen when someone has mutations to both the TAF/TDF and FTC (I think you posed this question to the DAWNING study team at CROI…). Seems risky.

Thanks!

Risa

This is the kind of detail one can’t put in a 10-minute conference presentation, so here it is:

Of the 30 participants in that first category (which is resistance to tenofovir by either K65R or lots of TAMS), 21 also had M184V/I (13 BIC, 8 DTG). Of these 21 participants, 4 had K65R with M184V (3 BIC, 1 DTG), and the rest (17) had TAMs with M184V (10 BIC, 7 DTG).

And none in either arm had treatment failure at week 48.

So where does that leave us?

In the setting of treatment failure, I’m quite comfortable that patients with M184V alone can be successfully treated with tenofovir (TAF or TDF)/FTC plus DTG. BIC/FTC/TAF would probably work too, though it hasn’t been tested.

For people who are already suppressed on an integrase-based or NNRTI-based regimen, they can be successfully managed with either DTG plus tenofovir/FTC or BIC/FTC/TAF, even if they have more than just M184V for NRTI resistance. There is enough residual activity of the NRTIs to let the high resistance barrier integrase inhibitors (DTG or BIC) do most of the work.

Two key remaining questions:

  • For treatment failure with K65R plus M184V, what is the best approach? ZDV is highly active against these viruses, but who wants to use it? Should it be DTG plus DRV/r? Something else?
  • For suppressed patients on NRTIs plus a boosted PI (and there are a lot of them in the world), can they be switched to DTG plus TAF/FTC or BIC/FTC/TAF? Even if we don’t know their resistance history?

When clinical research answers those questions, it will be time for The Curious Case of M184V, Part 3.

Hey, it’s still officially summer, at least until September 23 — let’s go swimming!

Categories: Health Care, HIV
Tags: , , , ,

(3) Comments
Permalink

September 2nd, 2019

New Antibiotics for CRE, Draft Lyme Guidelines, Cost of Measles Outbreaks, and More — a Labor Day ID Link-o-Rama

Labor Day! Could summer really be over?

Nah, we still have a few weeks — and as I’ve noted several times, this time of year (September-October) gives us far and away Boston’s best weather season.

On with the links.

(H/T to Keith Law for finding the cartoon.)

To finish — slow and steady wins the race (at least sometimes). I’ve watched this video too many times not to share it on this site, as it’s strangely compelling.

 

 

 

Categories: Health Care, HIV, Infectious Diseases
Tags:

(2) Comments
Permalink

August 25th, 2019

Save the Dates! International Scientific Conferences You Can’t Miss

On this beautiful summer Sunday, I’m sorting through a series of invitations to international scientific meetings.

So many options.

See, they really want me. And how do I know that my participation will be so important?

Just look how personalized the greetings are — clearly intended for me and me alone. I’ve included actual screen shots of the invitations as evidence for the careful thought that went into sending me — yes, me — these invitations.

To say I’m flattered barely begins to describe how these emails make me feel.

First up, from an “Auston Matthews”, who describes himself (herself?) as “Program Manager”:

Here’s what I wrote back:

Dear Mr./Ms. Matthews,

I’m very well indeed! And how are you? How are you enjoying the role of Program Manager?

Now that we’re done with the niceties, let me assure you — the privilege and honour are 100% mine. Being a Speaker towards the 3rd Global Experts Meeting on Infectious Diseases would be something special. I’ll highlight it on my CV in bright yellow marker. Please relay that (plus my best wishes) to the Organizing Committee Members, who no doubt are busy in London planning an exciting meeting.

Before I make my flight arrangements, where is “Bankok”? Is that near Bangkok?

With warm regards,

Dr. PE Paul E

Next — an email from a certain “Henry Walter, Conference Manager”, who generously offers me the chance to visit Rome!

Academic medicine, what a global endeavor!

My response:

Dear Henry Walter,

May I assume we both can communicate on a first-name basis, since you used mine? Hope that’s not too presumptuous!

And you bet I’ll participate in that conference! Not only were the first three iterations of the International Conference on Neurology and Brain Disorders (INBC) scintillating, but I’ve heard that the 4th — INBC 2020 — will absolutely rock.

Let’s speak ASAP about my topic, as I have some ideas. How about a lecture entitled, “Degenerative Brain Diseases of Fish”? After all, I’m the expert.

Hope this sounds INBC-worthy to you. I know the standards are very high!

Sincerely,

Default Value

On to invitation number three, which represents the very pinnacle of personalized conference invitations. It comes from a “Dr. Irene Frank”, whose title is “Executive Director, Coalesce Research Group”. They’re based in Greenville, South Carolina, in case you were wondering.

Here’s what I wrote back:

Dear Dr. Frank,

First, very warm wishes back to you! Speaking of, it must be hot this time of year down in South Carolina, ha ha.

Second — Plenary Speaker at Nano 2019, what an honor! I’m speechless. But don’t worry, I’ll get over it by November, and will be ready to go for my plenary talk. I’ll make sure it’s something BIG about this small (nano, get it?) topic. Ha ha again.

Third — just curious, is it hard to organize a conference in Osaka all the way from Greenville, South Carolina? Is there a direct flight? It’s amazing how you folks at Coalesce Research do all that you do, so impressive.

Finally, before formally agreeing to speak, I have to ask — how will you be introducing me? It’s just not clear from your invitation. And I confess — sometimes I feel like a nowhere man, sitting in a nowhere land, making all these nowhere plans, for nobody.

Regards,

“,”

Take it away, guys.

(Part of an occasional series, as these folks show no signs of tiring. And h/t to friend John Winkelman for the inspiration.)

Categories: Health Care, Infectious Diseases, Medical Education
Tags:

(11) Comments
Permalink

August 18th, 2019

Choosing the Top Research Papers in HIV Medicine — and Recalling the Joy of Working with a Great ID Fellow

Way back in 2008 — the year I started writing here — I drafted an exceedingly long post listing the top published papers in HIV medicine.

Oh how I tortured myself over that thing.

How to define “Top”? Most cited? Most clinically important? Most rigorously scientific? Best written?

After a while, I just abandoned the monstrosity. It still sits electronically somewhere in the NEJM Journal Watch servers, forlornly awaiting a revision.

Now, courtesy of my friend and colleague Dr. Raphael (Raphy) Landovitz from UCLA, the concept lives again. He joined me for the Open Forum Infectious Diseases (that’s “O-F-I-D”, not “Oh-fid”) podcast, where we each choose our top 5 research papers in HIV medicine — plus our least favorite.

Give it a listen, or read the transcript. We’re also on iTunes, where we’d appreciate a rating if you like what you hear.

Before leaving you, just a few words about Raphy and how great he was as an ID fellow. Since we’re ranking things, he’s easily among the top ID fellows I’ve ever worked with in my gazillion years of being an ID attending. Energetic, smart, compassionate, thorough — ticked all the boxes. He also was hysterically funny.

(Brief aside — working with great fellows is a true joy. On service or in clinic with them, you totally trust their clinical instincts, and end up finishing each other’s sentences while discussing a case. A wonderful synergy in academic medicine.)

After finishing his fellowship plus a few years on the faculty here, Raphy traded our cold Boston winters for the warmth (but geologic instability!) of Los Angeles. Under the the skillful mentorship of Dr. Judy Currier, he’s had a sensational research trajectory, focusing on HIV prevention. There is not a person on the planet who knows more about PrEP. And, just this month, Raphy was deservedly promoted to full Professor of Medicine at UCLA.

Hoping you’ll permit those of us involved in some way with his training to beam a little!

Categories: Health Care, HIV, Infectious Diseases, Medical Education

(1) Comment
Permalink

August 11th, 2019

The United States Needs Stricter Gun Control Now — and Yes, This Is an ID Issue

In general, I’ve tried to keep this site a pretty happy place.

It’s not been difficult. The ID and HIV community includes many smart, like-minded individuals involved in all sorts of interesting and challenging work, both domestically and abroad. As one of our ID fellows recalled, after he did a rotation in our ID clinic during his medical residency, “I realized I’d found my people.”

Today, however, I’m going to write about something on the sadder side, an issue tearing up our country.

We need stricter gun control in the United States. And we need it NOW.

Yes, this is a departure from prior controversies here, such as should doctors wear white coats, estimating the infectious risk of food tongs, or whether the correct abbreviation for P. jirovecii pneumonia is now PJP instead of PCP. 

I’m venturing into this more contentious* issue because it’s just too painful to ignore.

(*But to my dear readers of the ID persuasion, there’s an excellent chance you’re in complete agreement. And how do I know? Easy.)

How many of you thought, Oh no not again, when you heard the news of last week’s shooting in El Paso? And then less than 24 hours later, Oh no not again, with the news from Dayton?

And we could go on and on listing these mass shootings — sadly, we even have a Wikipedia page cataloguing them for us. It’s getting so bad that voices outside of the usual crowd feel compelled to weigh in — here’s sportswriter Joe Posnanski taking a break from his usual (brilliant) baseball coverage to write a poem describing his heartbreak.

It’s very moving. But a sportswriter writing a poem? Must be time to do something.

And lest some think this isn’t a problem related to Infectious Diseases, that I should “stay in my lane” — how wrong to think that. It’s a problem for all of us in healthcare, and, for several reasons, especially for us ID-specialists.

Crystal Zheng and David Mushatt, two ID doctors from New Orleans, astutely make the case:

During the initial hospitalization, gunshot wounds can become infected, causing skin and soft tissue infections, as well as intra-abdominal, thoracic, and brain abscesses ….Long after the initial event, gunshot survivors with spinal cord injury face a lifetime of disability, marked by recurrent infections due to autonomic dysfunction, decreased airway clearance, sensory loss, and paraplegia. These patients are at increased risk for urinary tract infections, pneumonias, infected sacral ulcers, and chronic osteomyelitis. Infection is the leading cause of death in this population. 

(Emphasis mine.)

Most of the cases we see, of course, aren’t from mass shootings. Events like El Paso and Dayton (and Gilroy and Newtown and Orlando and Parkland and Charlotte and Pittsburgh and …) get the big news, but there are way more injuries and deaths from individual shotgun wounds happening every day and night somewhere in our country.

For the victim, it doesn’t matter if the injury is from a mass shooting, an unfortunate urban skirmish, a heated domestic squabble, or the result of a deranged individual who has ready access to a gun. Their lives are irrevocably changed if they survive, often with infectious complications.

Yes, if they survive. If they don’t, those left behind suffer unbearable sadness and trauma at the loss — family, friends, colleagues. We have personal recent experience at our hospital when, in 2015, one of our rising stars in cardiac surgery was shot during an outpatient clinic session.

Oh no not again.

But look — it doesn’t have to be this way.

After last weekend’s events, I tweeted about the New Orleans perspective piece cited above, and received this response:

That’s right — 35 years of clinical ID practice, no gunshot wounds. Other countries have angry people. Other countries have urban violence. Other countries have terrorists. But only in the United States can these lead to such efficient killing.

And it’s the easy access to guns that makes our country an outlier in gun violence. It’s that simple:

I hope you’ll read the linked article, which debunks several popular alternative theories about why we have more gun violence (specifically mass shootings) than any other country. But if you don’t have the time:

Americans make up about 4.4 percent of the global population but own 42 percent of the world’s guns. From 1966 to 2012, 31 percent of the gunmen in mass shootings worldwide were American.

New Yorker writer Adam Gopnik has written frequently on this topic, perhaps because he lived in France, a place with far more sensible gun control. After the Orlando mass shooting in 2016, he wrote a piece called “One Person, One Gun” highlighting the horrible power we Americans grant our citizens — criminals, terrorists, people with mental illness, perpetrators of domestic violence — by giving them ready access to guns.

And it’s not just any handguns, but weapons designed for military use specifically to kill as many people as efficiently as possible:

So, yes, one person did do that, but it was a weapon that empowered him to do it—a weapon designed only for mass killing on the battlefield, a weapon so dangerous that soldiers keep their version locked up when not actually training with it, out of respect for its rapid-fire lethality, but a weapon that now, in Florida and elsewhere, can be placed freely and without constraints into the hands of almost anyone who wants one.

Last week, numerous medical organizations weighed in on the need for stricter gun control in this country, calling for specific actions that make so much sense it only adds to the pain that these restrictions are not already in place — among them, requiring background checks before sales, prohibiting gun ownership among those guilty of domestic violence, special regulation of high-capacity firearms, and removal of physician gag-orders on counseling about gun violence.

I can’t speak on behalf of the Infectious Diseases Society of America (our own medical society), even though I’m a member.

But I can unequivocally say that 100% of the ID clinicians I’ve spoken with agree that this is an urgent issue for all of us.

Take it away, Stephen. It may not be your funniest clip on the topic of gun control — search YouTube for “Stephen Colbert gun control”, there are plenty.

But it could be your most important.

 

 

Categories: Health Care, Infectious Diseases, Policy
Tags:

(23) Comments
Permalink

July 28th, 2019

Really Rapid Review — IAS 2019 Mexico City

Photo by Justine Camacho on Unsplash.

As I noted last week — and you did read last week’s post, didn’t you? — the International AIDS conference first took place in Mexico City in 2008. Last week we returned to this sprawling, vibrant city for the 2019 meeting.

It was an excellent, well-run conference — with one small complaint.

But more on that later… On to the content, a Really Rapid Review® of the highlights.

One big plus to this year’s conference — the number of research posters was smaller than usual, increasing the quality of accepted studies.

Also, being in Mexico City in the summer remains a joy, with cool weather (remember the altitude!), friendly people, extraordinary sites and cuisine, and relatively reasonable prices.

My only complaint? No, not the traffic — that’s terrible in every big city.

It was the conference Wi-Fi, which tortured every attendee in a particularly excruciating way. Your computer and/or phone would indicate everything A-OK, no problem, then give access to the internet in brief spurts, lasting at most seconds — followed by prolonged periods of unresponsiveness. Completely impossible to do anything.

Yes, I’ll get over it.

Categories: Health Care, HIV, Infectious Diseases, Research
Tags:

(8) Comments
Permalink
Older Entries
Newer Entries
HIV Information: Author Paul Sax, M.D.

Paul E. Sax, MD

Contributing Editor

NEJM Journal Watch
Infectious Diseases

Biography | Disclosures | Summaries

Learn more about HIV and ID Observations.